Tildrakizumab-Asmn (Ilumya™)

Ilumya (tildrakizumab-asmn) is covered only for adults (≥18) with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy and is limited to the FDA‑approved indication (off‑label uses and patients <18 are excluded). Coverage requires prescription by or consultation with a dermatologist and a ≥3‑month trial or intolerance to at least one systemic or biologic psoriasis agent (or documented methotrexate contraindication); initial approval is 3 months (renewal 12 months) and reauthorization requires ≥90 days on therapy with documented clinical improvement in BSA, erythema, induration/thickness and/or symptoms.

"Has a contraindication to methotrexate therapy."

Sign up to see full coverage criteria, indications, and limitations.